Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)

NCT06315738 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Necrotizing Enterocolitis

Interventions

BIOLOGICAL: ST266

Sponsor

Noveome Biotherapeutics, formerly Stemnion

Collaborators

[object Object]